BMS-332

• UNSPSC Description:

  BMS-332 is adualDGKα/ζlipid kinase inhibitor, with theIC50of 0.005 (DGKα) and 0.001 μM (DGKζ)[1].

• Target Antigen:

  DGK

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/bms-332.html

• Solubility:

  DMSO : 14.29 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  CN(C1=CC=C(C#N)N=C1C(N2C[C@@H](C)N(C(C3=CC=C(F)C=C3)C4=CC=C(F)C=C4)C[C@@H]2C)=C5)C5=O

• Molecular Weight:

  499.55

• References & Citations:

  [1]Wichroski M, et al. DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell-mediated antitumor immunity. Sci Transl Med. 2023;15(719):eadh1892.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2407892-15-1